11 November 2013

ApoCell, Inc. Establishes Laboratory in Leipzig, Germany

Houston, TX – 11 November 2013 - ApoCell, Inc. has expanded into Europe and established offices and laboratories in Leipzig, Germany to better serve existing clients and capitalize on growing opportunities to provide its leading-edge molecular biomarker detection and analysis services to new European clients. ApoCell also announced a new collaboration with the Fraunhofer Institute for Cell Therapy and Immunology (IZI), a non-profit German research institute, to further develop ApoCell's proprietary circulating tumor cell (CTC) isolation technology, ApoStream® for clinical applications. ApoCell Europe GmbH, a newly formed division of privately-held ApoCell, Inc. will facilitate the partnership with Fraunhofer IZI.

"Our opportunities in Europe continue to grow and have led to this strategic expansion," said Darren Davis, president and CEO of ApoCell. He added that ApoCell's European office will primarily serve to enhance communication and collaboration with existing clients and to develop new clinical trial services business.

ApoCell's Christoph Sachsenmaier, vice president of business development - Europe, will lead activities to expand the biomarker clinical trial services. A molecular biologist by training with a Ph.D. from University of Innsbruck, Austria, Sachsenmaier has more than 20 years of experience in the biotechnology and life sciences sector.

As part of the cooperative project with Fraunhofer IZI, ApoCell will continue to develop the ApoStream® device, optimize technical parameters, improve ease of operation and increase system performance efficiency. "We have declared it our goal to develop a FDA Class I, CE marked investigational use only (IUO) instrument within the next year for use in clinical studies to generate data for in vitro diagnostic applications," said Davis, who serves as managing director of ApoCell Europe GmbH.

The project, valued at approximately four million Euros, is being funded through the Sächsische Aufbaubank (Saxon Development Bank) with a total of three million Euros coming from the European Regional Development Fund (ERDF) and also from the Free State of Saxony.

Based in Houston, ApoCell is a privately-held specialty clinical research company. Founded in 2004, the firm is a leader in molecular biomarker detection and analysis. The company's facilities are CLIA-certified and compliant with applicable FDA regulations. Since inception, the company has participated in over 140 Phase I, II, and III clinical cancer drug trials for more than 80 sponsor clients worldwide.

Source: ApoCell